Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Inositol polyphosphate 4-phosphatase
B (INPP4B) has been identified as a tumour suppressor in different human cancers. However, the role of INPP4B in the angiogenesis of human
prostate cancer
cells remains unclear. In this study, we first compared the expression of INPP4B between
prostate cancer
tissues and tumour-adjacent normal prostate tissues using immunohistochemistry. Then, we explored the role of INPP4B in
prostate cancer
progression via transfection of a Flag-INPP4B plasmid into PC3 and DU145 cells in vitro and in vivo. Our results showed that reduced INPP4B staining was significantly correlated with the tumour-node-metastasis stage. Moreover, transfection with Flag-INPP4B plasmid suppressed the migration and invasion of
prostate cancer
cells through inactivating the PI3K/Akt signalling pathway, at the same time decreased vascular endothelial growth factor secretion and suppressed human umbilical vein endothelial cells proliferation and tube formation. Futhermore, it was also found that INPP4B could inhibit tumour growth and angiogenesis in vivo. Altogether, our results supported that INPP4B acted as a tumour suppressor in human
prostate cancer
, and provided insights into development of a targeted therapy for this disease.
...
PMID:INPP4B overexpression suppresses migration, invasion and angiogenesis of human prostate cancer cells. 2826 55
Inositol polyphosphate 4-phosphatase type II
emerges as a tumor suppressor in
prostate cancer
, and its loss of expression is associated with poor prognosis for
prostate cancer
. However, the mechanism of downregulation of inositol polyphosphate 4-phosphatase type II in
prostate cancer
development has not yet been fully clarified. In this study, microRNA-590-3p was found to be upregulated in both
prostate cancer
tissues and cell lines. Overexpression of microRNA-590-3p by microRNA-590-3p mimics promoted
prostate cancer
cell proliferation and invasion and accelerated the growth of xenografted tumors, while microRNA-590-3p inhibitors contributed to inhibition of cellular proliferation and invasion as well as tumor growth. A dual-luciferase reporter assay and expression analysis further confirmed that inositol polyphosphate 4-phosphatase type II was a direct target of microRNA-590-3p. Enforced expression of microRNA-590-3p led to repression of inositol polyphosphate 4-phosphatase type II messenger RNA and protein expression, as well as upregulation of p-Akt, p-FoxO3a, and cyclin D1 and downregulation of p21 expression in
prostate cancer
cell lines. Overexpression of inositol polyphosphate 4-phosphatase type II could reduce microRNA-590-3p-induced cell proliferation and invasion as well as tumor growth, and decrease microRNA-590-3p-mediated upregulation of cyclin D1 and downregulation of p21 expression in
prostate cancer
cells. Taken together, our findings reveal that microRNA-590-3p is a potential onco-microRNA that participates in carcinogenesis of human
prostate cancer
by suppressing inositol polyphosphate 4-phosphatase type II expression and involving the Akt/FoxO3a pathway. MicroRNA-590-3p may represent a potential therapeutic target for
prostate cancer
patients.
...
PMID:MicroRNA-590-3p promotes cell proliferation and invasion by targeting inositol polyphosphate 4-phosphatase type II in human prostate cancer cells. 2834 64